The policy brief summarizes key findings from an assessment of hepatitis C treatment accessibility in Eastern Europe and Central Asia (EECA) undertaken by the Eurasian Harm Reduction Network (EHRN).
Mapping was conducted in six countries of EECA. The main goal of the mapping was to assess access to pegylated interferon and ribavirin. Based on the mapping's findings, EHRN has formulated recommendations on how to remove the identified barriers to access and improve the situation. These recommendations target both international stakeholders, including WHO and multinational pharmaceutical companies, as well as national ones.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.